

[x](#)

How to Use

- **Searching:** Type keyword in search field at top of page. Search by all or part of a monograph title. For searches using multiple criteria, you will find items that match each of the specified criteria unless quotation marks are used.
 - For example, a search on Aminosalicyclic Acid Tablets will result in anything that contains “Aminosalicyclic” OR “Acid” OR “Tablets”
 - A search for “Aminosalicyclic Acid Tablets” will result in anything that specifically contains “Aminosalicyclic Acid Tablets”
- **Sorting:** Click on any column header title to sort alphabetically or chronologically in ascending or descending order. Note: the page load column is sorted alphabetically so that a number is ordered by first digit vs. by the actual number; thus, numbers will not always be in order.
 - For example, page 2178 will come before page 74 on a page sort.
- **Downloading:** You can download the Errata table in Comma-separated Value (.csv). The download will include the Errata that you have filtered on.
- **Importing:** You will need to import the file into Excel or Open Office with UTF-8 encoding, as opposed to simply opening it. To import, open Excel or Open Office and select import from the File drop-down. Depending on the version you are using, you should be presented with import formatting options to include UTF-8 as one of the first steps. Importing via UTF-8 should eliminate odd character conversions.

Monograph Title	Section	Source	Page Number	Errata Post	Errata Official	Target Errata	Target Online	Description
		Publication		Date	Date	Print Publication	Fix Publication	
POWDERED	COMPOSITION	USP37–NF32	5456	30-May-2014	1-Jun-2014	USP38–NF33	USP38–NF33	Line 4 of

Monograph Title Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
HOLY BASIL LEAF	<i>/Content of Triterpenes</i>						<i>Standard solution B: Change 0.45-?L to: 0.45-?m</i>
ACETAMINOPHEN SUPPOSITORIES	<i>ASSAY/ Procedure</i>	USP37–NF32 1567	30-May-2014	1-Jun-2014	USP38–NF33	USP38–NF33	Line 6 of <i>Sample stock solution:</i> Change add 30 mL of hexane, to: add 30 mL of solvent hexane, AND Line 10 of <i>Sample stock solution:</i> Change wash the hexane to: wash the solvent hexane
PSEUDOEPHEDRINE HYDROCHLORIDE, AND RBINOXAMINE MALEATE, AND DEXTRO	<i>Microbial enumeration tests <61> and Tests for specified microorganisms</i>	USP37–NF32 4486	30-May-2014	1-Jun-2014	USP38–NF33	USP38–NF33	Line 3: Change does not exceed 100 per g, the total combined molds and

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
METHORPHAN <62> HYDROBROMI DE ORAL SOLUTION									yeasts count does not exceed 10 per g, to: does not exceed 10 ² cfu/g, the total combined molds and yeasts count does not exceed 10 ¹ cfu/g,
PHENYTOIN SODIUM INJECTION	OTHER COMP ONE NTS/Alcohol and Propylene Glycol Content	<i>First Supplement to USP37–NF32</i>	6684	30-May-2014		1-Jun-2014	<i>USP38–NF33</i>	<i>USP38–NF33</i>	Line 3 of <i>Standard solution</i> : Change <i>Internal standard stock solution</i> to: <i>Internal standard solution</i>
ANTIBIOTICS—MICROBIAL ASSAYS	Turbidimetric Method	<i>USP36–NF31</i>	76	28-Mar-2014		1-Apr-2014	<i>USP38–NF33</i>	<i>USP38–NF33</i>	Line 9 of Paragraph 2 of <i>Analysis</i> : Change or a water bath maintained at

Monograph Title Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
ONDANSETRO <i>Related</i> N ORAL <i>compounds</i> SOLUTION	USP36–NF31	4586	28-Mar-2014	1-Apr-2014	USP38–NF33	USP38–NF33	<p>the temperature specified in <i>Table 8</i> and for the time specified in <i>Table 11</i>. to: or a water bath maintained at 36.0° –37.5° for the time specified in <i>Table 11</i>.</p> <p>Line 7 of <i>Procedure</i>: Change (293.36/329.82) 10,000(1 / F)(1 / V)(C_S / C_A)(r_i / r_s) to: (293.36 / 329.83)10,000(1 / F)(1 / V)(C_S / C_A)(r_i / r_s) AND Line 8 of <i>Procedure</i>: Change 329.82 to:</p>

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
ATROPINE SULFATE INJECTION	ASSAY/ Procedure	<i>First Supplement to USP36–NF31</i>	5950	28-Mar-2014		1-Apr-2014	<i>USP38–NF33</i>	<i>USP38–NF33</i>	329.83 Line 1 of <i>Buffer</i> . Change Dissolve 4.1 g of sodium acetate and to: Dissolve 4.1 g of anhydrous sodium acetate and
PHARMACEUTICAL COMPOUNDING—NON STERILE PREPARATIONS	COMPOUNDING FACILITIES	<i>Revision Bulletin (Official January 01, 2014)</i>	Online	28-Mar-2014		1-Apr-2014	<i>Second Supplement to USP37–NF32</i>	<i>Second Supplement to USP37–NF32</i>	Line 4 of Paragraph 4: Change (see the <i>General Notices and Requirements, Preservation, Packaging, Storage, and Labeling, Storage Temperature and Humidity</i> , to: (see <i>Packaging and Storage Requirements <659></i> ;
CLINDAMYCIN ASSAY/		<i>USP36–NF31</i>	3031	28-Mar-2014		1-Apr-2014	<i>USP38–NF33</i>	<i>USP38–NF33</i>	Line 1 of

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
PALMITATE HYDROCHLORIDE	<i>Procedure</i>								<i>Acceptance criteria:</i> Change NLT 540 ?g to: NLT 540 ?g/mg
THALIDOMIDE CAPSULES	<i>Dissolution <711></i>	<i>USP36–NF31</i>	5347	28-Mar-2014		1-Apr-2014	<i>USP38–NF33</i>	<i>USP38–NF33</i>	After the <i>Test solution</i> section: Add to: <i>Chromatographic system</i> —Prepare as directed in the Assay under <i>Thalidomide</i> .
CALCIUM SULFATE	<i>ASSAY/ Procedure</i>	<i>First Supplement to USP36–NF31</i>	Online	28-Mar-2014		1-Apr-2014	<i>USP38–NF33</i>	<i>USP38–NF33</i>	Line 14 of <i>Analysis:</i> Change Result = $[(V \times N \times F)/W] \times 100$ to: Result = $[(V \times M \times F)/W] \times 100$ AND Line 15 of <i>Analysis:</i> Change V = volume of titrant consumed by the Sample

Monograph Title Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
							(mL) <i>N</i> = actual normality of the titrant (mEq/mL) <i>F</i> = equivalency factor, 136.14 mg/mEq to: <i>V</i> = volume of <i>Titrant</i> consumed by the <i>Sample</i> (mL) <i>M</i> = actual molarity of the <i>Titrant</i> (mM/mL) <i>F</i> = equivalency factor, 136.14 mg/mM
Sodium Sulfite, RE Anhydrous	USP36–NF31	1196	28-Mar-2014	1-Apr-2014	USP38–NF33	USP38–NF33	Line 2: Change [7753-83-7] to: [7757-83-7]
AGEN TS/Reagent Specifications							
ONDANSETRO Assay	USP36–NF31	4586	28-Mar-2014	1-Apr-2014	USP38–NF33	USP38–NF33	Line 7 of <i>Procedure</i> : Change (293.36/329.82) 100(<i>C/V</i>)(<i>r_U</i> / <i>r_S</i>) to: (293.36 / 329.83)100(<i>C</i> /
N ORAL SOLUTION							

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Errata Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
									$V(r_U / r_S)$ AND Line 8 of <i>Procedure:</i> Change 329.82 to: 329.83
BUTYLPARABEN	IM PURITIES/Related Substances/ Chromatographic system	<i>Second Supplement to USP36–NF31</i>	6551	28-Mar-2014		1-Apr-2014	<i>USP38–NF33</i>	<i>USP38–NF33</i>	After the <i>Column</i> section: Add <i>Column temperature:</i> 35°
PHARMACEUTICAL COMPOUNDING—NONSTERILE PREPARATIONS	STABILITY CRITERIA AND BEYOND-USE DATIN/General Guidelines for Assigning Beyond-Use Dates	<i>Revision Bulletin (Official January 01, 2014)</i>	Online	28-Mar-2014		1-Apr-2014	<i>Second Supplement to USP37–NF32</i>	<i>Second Supplement to USP37–NF32</i>	Line 7 of Paragraph 1: Change (see the <i>General Notices and Requirements, Preservation, Packaging, Storage, and Labeling</i>) to: (see <659>)
MELPHALAN TABLETS	<i>Dissolution <711></i>	<i>USP36–NF31</i>	4232	28-Mar-2014		1-Apr-2014	<i>USP38–NF33</i>	<i>USP38–NF33</i>	Line 1 of <i>Mobile phase:</i> Change Prepare a

Monograph Title Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
							<p>filtered and degassed mixture of water, acetonitrile, ammonium acetate, glacial acetic acid, and triethylamine (1 500:500:2:2:0.4). Make adjustments if necessary (see <i>System Suitability</i> under <i>Chromatography</i> <621>).</p> <p>to:</p> <p>Transfer 2 grams of ammonium acetate, 2 mL of glacial acetic acid, and 0.4 mL of triethylamine to a suitable flask containing 1500 mL of water and 500 mL of acetonitrile. Stir</p>

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
THIMEROSAL	IM PURITIES/ <i>Mercury Ions</i>	<i>USP36–NF31</i>	5368	28-Mar-2014		1-Apr-2014	<i>USP38–NF33</i>	<i>USP38–NF33</i>	until all solids are dissolved and well mixed, then filter and degas. Line 19 of <i>Analysis</i> : $C_S =$ concentration of mercuric chloride in the <i>Standard solution</i> (mg/mL) to: $C_S =$ concentration of mercuric chloride in <i>Sample solution B</i> (mg/mL)
ONDANSETRON INJECTION	Assay	<i>Second Supplement to USP36–NF31</i>	Online	28-Mar-2014		1-Apr-2014	<i>USP38–NF33</i>	<i>USP38–NF33</i>	Line 7 of <i>Procedure</i> : Change (293.36 / 329.82)(25C / V)(r_U / r_S) to: (293.36 / 329.83)(25C / V)(r)

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
MAGNESIUM ALUMINUM SILICATE	IM PUR ITIES/ <i>Arsenic</i> , <i>Method I <211></i>	<i>USP36–NF31</i>	2073	28-Mar-2014		1-Apr-2014	<i>USP38–NF33</i>	<i>USP38–NF33</i>	<p><i>u/ r_s</i>) AND Line 8 of <i>Procedure</i>: Change 329.82 to: 329.83</p> <p>Line 1 of <i>Standard preparation</i>: Change Prepare as directed in the chapter. to: Transfer 5.0 mL (5 ?g of arsenic) of the <i>Standard Arsenic Solution</i> to a 25-mL volumetric flask, and add dilute hydrochloric acid (1:25) to volume. AND Delete: <i>Control preparation</i>: Transfer 5.0 mL</p>

Monograph Title Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
							<p>(5 ?g of As) of the <i>Standard preparation</i> to a 25-mL volumetric flask, and add dilute hydrochloric acid (1:25) to volume.</p> <p>AND</p> <p>Line 1 of <i>Acceptance criteria</i>: Change the absorbance due to any red color from the <i>Test preparation</i> does not exceed that produced by the <i>Control preparation</i>.</p> <p>to:</p> <p>the absorbance due to any red color from the <i>Test preparation</i> does not exceed that</p>

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
SODIUM ACETATE	IM PURITIES/ <i>Inorganic Impurities/Potassium</i>	USP36–NF31	5147	28-Mar-2014		1-Apr-2014	USP38–NF33	USP38–NF33	<p>produced by the <i>Standard preparation</i>.</p> <p>Line 1 of <i>Sample solution</i>: Change Equivalent to 600 mg/mL of anhydrous sodium acetate to: Dissolve the equivalent of 3 g of anhydrous sodium acetate in 5 mL of water. AND Line 1 of <i>Analysis</i>: Change To 5 mL of <i>Sample solution</i> add to: To the <i>Sample solution</i> add</p>
CARBIDOPA AND LEVODOPA	ASSAY	<i>Second Supplement to USP36–NF31</i>	6580	28-Mar-2014		1-Apr-2014	USP38–NF33	USP38–NF33	<p>Line 2 of <i>Procedure</i>: Change</p>

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
ORALLY DISINTEGRATING TABLETS									Inject the <i>Sample solution</i> within 2 h of preparation. Protect the volumetric solutions from light. to: Protect the volumetric solutions from light.
OIL- AND WATER-SOLUBLE VITAMINS WITH MINERALS CAPSULES	STREN GTH/ <i>Molybdenum, Method 1</i>	<i>Second Supplement to USP36–NF31</i>	6372	31-Jan-2014		1-Feb-2014	<i>USP38–NF33</i>	<i>Second Supplement to USP37–NF32</i>	Line 2 of <i>Standard solutions</i> : Change 2.0 to: 5.0
GLYCERYL TRISTEARATE	IDENTIFICATION/ <i>Fatty Acid Composition</i>	<i>USP36–NF31</i>	2033	31-Jan-2014		1-Feb-2014	<i>USP38–NF33</i>	<i>Second Supplement to USP37–NF32</i>	Line 19 of <i>Analysis</i> : Change Result = $[(F_{MC} \times P_{FA1} \times A_{MC}) / (P_{MC} \times A_{FA1})] \times 100$ to: Result = $(F_{MC} \times P_{FA1} \times A_{MC}) / (P_{MC} \times A_{FA1})$

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
DICLOFENAC SODIUM DELA YED-RELEASE TABLETS	IM PUR ITIES/ <i>Organic</i> <i>Impurities/Procedure</i>	<i>USP36–NF31</i>	3221	31-Jan-2014		1-Feb-2014	<i>USP38–NF33</i>	<i>Second Supplement to USP37–NF32</i>	Line 22 of <i>Analysis:</i> Change r_s = peak response for each impurity from the <i>Standard solution</i> to: r_s = peak response of diclofenac related compound A from the <i>Standard solution</i>
TIZANIDINE TABLETS	IM PUR ITIES/ <i>Organic</i> <i>Impurities/Procedure</i>	<i>USP36–NF31</i>	5408	31-Jan-2014		1-Feb-2014	<i>USP38–NF33</i>	<i>Second Supplement to USP37–NF32</i>	Line 9 of <i>Sample solution:</i> Change 45- μ m or finer pore size to: 0.45- μ m or finer pore size
OXALIPLATIN INJECTION	IM PURITIES/ <i>Limit of Oxalic Acid</i>	<i>First Supplement to USP36–NF31</i>	6033	31-Jan-2014		1-Feb-2014	<i>USP38–NF33</i>	<i>Second Supplement to USP37–NF32</i>	Line 3 of <i>Analysis:</i> Change Calculate the

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Errata Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
WATER-SOLUBLE VITAMINS WITH MINERALS CAPSULES	ST REN GTH/ <i>Molybdenum, Method 1</i>	<i>Second Supplement to USP36–NF31</i>	6479	31-Jan-2014		1-Feb-2014	<i>USP38–NF33</i>	<i>Second Supplement to USP37–NF32</i>	percentage of each impurity to: Calculate the percentage of oxalic acid Line 2 of <i>Standard solutions</i> : Change 2.0 to: 5.0
CEFTAZIDIME FOR INJECTION	<i>Assay</i>	<i>USP36–NF31</i>	2887	31-Jan-2014		1-Feb-2014	<i>USP38–NF33</i>	<i>Second Supplement to USP37–NF32</i>	Line 6 of <i>Procedure</i> : Change $250,000\{C/W(100 ? m ? s)\}(r_U / r_S)$ to: $25,000\{C/[W(100 ? m ? s)]\}(r_U / r_S)$
RIBOFLAVIN 5 ?-PHOSPHATE PURITIES/ SODIUM	IM <i>Riboflavin and Riboflavin Diphosphates</i>	<i>USP36–NF31</i>	5037	31-Jan-2014		1-Feb-2014	<i>USP38–NF33</i>	<i>Second Supplement to USP37–NF32</i>	Line 1 of <i>Emission wavelength</i> : Change 530 nm to: 530 nm (monochromator-based)

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
CYCLOMETHI CONE	ASSAY/ Proce dure/System suitability	<i>First Supplement to USP36–NF31</i>	5909	31-Jan-2014		1-Feb-2014	<i>USP38–NF33</i>	<i>Second Supplement to USP37–NF32</i>	detector) or 470 nm (filtered-type detector) Line 2 of Suitability requirements: Change <i>Relative standard deviation</i> : NMT 2.0% for cyclomethicone 4, cyclomethicone 5, and cyclomethicone 6, <i>Standard solution A, Standard solution B, and Standard solution C</i> to: <i>Relative standard deviation</i> : NMT 2.0% for cyclomethicone 4, <i>Standard solution A</i> ; NMT 2.0% for

Monograph Title Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
OIL- AND WATER-SOLUBLE VITAMINS WITH MINERALS ORAL SOLUTION	STREN GTH/ <i>Chromium USP36–NF31</i>	6399	31-Jan-2014	1-Feb-2014	USP38–NF33	<i>Second Supplement to USP37–NF32</i>	cyclomethicone 5, <i>Standard solution B</i> ; NMT 2.0% for cyclomethicone 6, <i>Standard solution C</i> Line 13 of <i>Analysis</i> : Change C = concentration of chromium in the <i>Standard solution</i> (µg/mL) to: C = concentration of chromium in the <i>Sample solution</i> (µg/mL)
ANAGRELIDE HYDROCHLORIDE ASSAY/Procedure/ <i>Chromatographic system/System suitability</i>	USP36–NF31	2500	31-Jan-2014	1-Feb-2014	USP38–NF33	<i>Second Supplement to USP37–NF32</i>	Line 2 of <i>Suitability requirements</i> : Change <i>Column efficiency</i> : NMT to: <i>Column efficiency</i> : NLT
DILTIAZEM HYDROCHLORIDE IM	USP36–NF31	3258	31-Jan-2014	1-Feb-2014	USP38–NF33	<i>Second</i>	Line 21 of

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
DROCHLORID E	PURITIES/ <i>Organic Impurities</i>							<i>Supplement to USP37–NF32</i>	<i>Analysis: Change r_S = response of each impurity peak from the Standard solution to: r_S = peak response of desacetyl diltiazem from the Standard solution</i>
VANCOMYCIN HYDROCHLORIDE	SPECIFIC TESTS/ <i>Composition of Vancomycin</i>	<i>USP36–NF31</i>	5543	31-Jan-2014		1-Feb-2014	<i>USP38–NF33</i>	<i>Second Supplement to USP37–NF32</i>	Line 28 of <i>Analysis: Change Result = $[(r_V/(D \times r_B) + r_A)] \times 100$ to: Result = $\{r_V/[(D \times r_B) + r_A]\} \times 100$</i>
CONTAINERS GLASS-EVALUATION OF INNER SURFACE DURABILITY	EVALUATION OF THE INNER SURFACE DURABILITY/ <i>Aggressive</i>	<i>Second Supplement to USP36–NF31</i>	6221	31-Jan-2014		1-Feb-2014	<i>USP38–NF33</i>	<i>Second Supplement to USP37–NF32</i>	Row 1 of Column 3 of <i>Table 4: Change 3% Citric Acid pH 8.0 to:</i>

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
ISOPROPYL ALCOHOL	Screening Conditions ASSAY/ Procedure	Second Supplement to USP36–NF31	6638	31-Jan-2014		1-Feb-2014	USP38–NF33	Second Supplement to USP37–NF32	3% Sodium Citrate pH 8.0 Line 17 of Chromatographic system: Change Linear velocity: 35 cm/s to: Flow rate: 2.3 mL/min AND Row 2 of Column 1 of Table 2: Change Diethyl ether to: Ethyl ether
CLARITHROM YCIN	ASSAY/ Procedure/System suitability	USP36–NF31	3016	31-Jan-2014		1-Feb-2014	USP38–NF33	Second Supplement to USP37–NF32	Line 1 of Samples: Change Standard solution 2 and Standard solution 4 to: Standard solution 1, Standard solution 2, and

Monograph Title Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
RISPERIDONE TABLETS	<i>Dissolution <711></i>	USP36–NF31 5065	31-Jan-2014	1-Feb-2014	USP38–NF33	Second Supplement to USP37–NF32	<p><i>Standard solution 4 AND Line 13 of Suitability requirements: Change Relative standard deviation: NMT 1.5%, Standard solution 2 to: Relative standard deviation: NMT 1.5%, Standard solution 1</i></p> <p>Line 4 of <i>Chromatographic system: Change Chromatograph the Standard solution and the Test solution as directed for Procedure: to: Chromatograph the Standard</i></p>

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Errata Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
ATOMOXETIN E HYDROCHL ORIDE	IM PUR ITIES/ <i>Organic Impurities, Procedure 2</i>	<i>First Supplement to USP36–NF31</i>	5947	31-Jan-2014		1-Feb-2014	<i>USP38–NF33</i>	<i>Second Supplement to USP37–NF32</i>	<i>solution as directed for Procedure: Line 5 of System suitability solution: Change dissolving the Reference Standards in ethanol, to: dissolving the Reference Standards in absolute alcohol, AND Line 2 of Sample solution: Change dissolving it in ethanol, to: dissolving it in absolute alcohol, Add the test: Absence of</i>
OIL- AND WAT ER-SOLUBLE	CONTAMINAN TS	<i>Second Supplement to</i>	6399	31-Jan-2014		1-Feb-2014	<i>USP38–NF33</i>	<i>Second Supplement to</i>	

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
VITAMINS WITH MINERALS ORAL SOLUTION		USP36–NF31						USP37–NF32	Specified Microorganisms <2022>: Meet the requirements of the tests for the absence of <i>Salmonella</i> species, <i>Escherichia coli</i> , and <i>Staphylococcus aureus</i>
CANDESARTAN CILEXETIL ASSAY/	Procedure	USP36–NF31	2774	31-Jan-2014		1-Feb-2014	USP38–NF33	Second Supplement to USP37–NF32	Line 1 of Analysis: Change Titrate with 8 mL of 0.1 N to: Titrate with 0.1 N
FENTANYL	IMPURITIES/Organic Impurities/Acceptance criteria	USP36–NF31	3554	31-Jan-2014		1-Feb-2014	USP38–NF33	Second Supplement to USP37–NF32	Footnote f of Table 2: Change N-Phenyl-N-[1-(2-phenylethyl)-4-piperidiny] acetanilide hydrochloride,

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
VANCOMYCIN SPECIFIC HYDROCHLORIDE FOR INJECTION		USP36–NF31	5546	31-Jan-2014		1-Feb-2014	USP38–NF33	Second Supplement to USP37–NF32	or acetyl fentanyl. to: <i>N</i> -(1-Phenethylpiperidin-4-yl)- <i>N</i> -phenylacetamide. Line 27 of Analysis: Change Result = $[r_i / (D \times r_B) + r_A] \times 100$ to: Result = $\{r_i / [(D \times r_B) + r_A]\} \times 100$
LACTATED RINGER'S INJECTION	Definition	USP36–NF31	5055	22-Nov-2013		1-Dec-2013	USP38–NF33	Second Supplement to USP37–NF32	Line 13: Change 408.0 mg of chloride to: 428.0 mg of chloride
BUFFER SOLUTIONS	4. Standard Buffer Solutions/4.1 Preparation	Second Supplement to USP36–NF31	6244	22-Nov-2013		1-Dec-2013	USP38–NF33	Second Supplement to USP37–NF32	Line 1 of 4. Boric Acid and Potassium Chloride 0.2 M: Change

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Errata Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
DIVALPROEX SODIUM EXTENDED-RELEASE TABLETS	PERFORMANCE TESTS/ <i>Dissolution</i> <711>/Test 5	<i>Second Supplement to USP36–NF31</i>	6592	22-Nov-2013		1-Dec-2013	<i>USP38–NF33</i>	<i>Second Supplement to USP37–NF32</i>	12.73 g/L of boric acid to: 12.37 g/L of boric acid Line 3 of <i>Acid stage sample solution</i> : Change suitable filter of 45-µm pore size. to: suitable filter of 0.45-µm pore size. AND Line 3 of <i>Buffer stage sample solution</i> : Change suitable filter of 45-µm pore size. to: suitable filter of 0.45-µm pore size.
ALMOND OIL	SPECIFIC TESTS/ <i>Sterol Composition</i>	<i>USP36–NF31</i>	1877	22-Nov-2013		1-Dec-2013	<i>USP38–NF33</i>	<i>Second Supplement to USP37–NF32</i>	Row 9 of <i>Table 2</i> : Change ?7-Stigmastenol

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Errata Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
FLUOCINONID E TOPICAL SOLUTION	<i>Alcohol content</i>	<i>USP36–NF31</i>	3618	22-Nov-2013		1-Dec-2013	<i>USP38–NF33</i>	<i>Second Supplement to USP37–NF32</i>	<p>3.0% to: 7-Stigmasteno l 3.0% Line 1 of <i>Standard solution:</i> Change Dilute 20.0 mL of USP Alcohol to: Dilute 20.0 mL of alcohol</p>
MINERAL OIL	SPECIFIC TESTS	<i>USP36–NF31</i>	4372	22-Nov-2013		1-Dec-2013	<i>USP38–NF33</i>	<i>Second Supplement to USP37–NF32</i>	<p>Line 1 of <i>Viscosity—Capillary Viscometer Methods <911>:</i> Change 34.5 and 150.0 mm²· s^{−1} to: 34.5–150.0 mm²· s^{−1}</p>
ATROPINE SULFATE	SPECIFIC TESTS/ <i>Optical Rotation, Specific Rotation <781></i>	<i>First Supplement to USP36–NF31</i>	5948	22-Nov-2013		1-Dec-2013	<i>USP38–NF33</i>	<i>Second Supplement to USP37–NF32</i>	<p>Line 1 of <i>Sample solution:</i> Change 0.1 mg/mL in water to: 0.1 g/mL of</p>

Monograph Title Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
							Atropine Sulfate in water

Pagination

- [First page « First](#)
- [Previous page ‹ Previous](#)
- ...
- [Page 30](#)
- [Page 31](#)
- [Page 32](#)
- [Page 33](#)
- [Page 34](#)
- [Page 35](#)
- [Page 36](#)
- [Page 37](#)
- [Page 38](#)
- ...
- [Next page Next ›](#)
- [Last page Last »](#)